AAVantgarde Bio Srl
🇮🇹Italy
- Country
- 🇮🇹Italy
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.aavantgarde.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 1
1 (50.0%)A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- AAVantgarde Bio Srl
- Target Recruit Count
- 75
- Registration Number
- NCT07161544
- Locations
- 🇺🇸
Retina Consultants of Texas, Bellaire, Texas, United States
🇺🇸Retina Foundation of the Southwest, Dallas, Texas, United States
An Observational Study in Children and Adults With Stargardt Disease
Recruiting
- Conditions
- Stargardt Disease
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- AAVantgarde Bio Srl
- Target Recruit Count
- 80
- Registration Number
- NCT06591806
- Locations
- 🇳🇴
Oslo University hospital Ullevål, Oslo, Norway
🇺🇸Retina Foundation of the Southwest, Dallas, Texas, United States
Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- AAVantgarde Bio Srl
- Target Recruit Count
- 15
- Registration Number
- NCT06591793
- Locations
- 🇮🇹
University of Campania Luigi Vanvitelli, Naples, Italy
🇬🇧Moorfields Eye Hospital, London, United Kingdom
🇬🇧Retina Clinic London, London, United Kingdom
News
No news found